إعلان
إعلان

ORIC

ORIC logo

Oric Pharmaceuticals, Inc. Common Stock

9.14
USD
برعاية
+0.69
+8.20%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

9.21

+0.07
+0.72%

تقارير أرباح ORIC

النسبة الإيجابية المفاجئة

ORIC تفوق 12 من 23 آخر التقديرات.

52%

التقرير التالي

بيانات التقرير القادم
١٦ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.36
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
+9.09%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-29.41%

Oric Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On ١٣ نوفمبر ٢٠٢٥, ORIC reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.41 USD, resulting in a 20.14% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.49% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 المحللين forecast an EPS of -0.36 USD, with revenue projected to reach -- USD, implying an زيادة of 9.09% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, Oric Pharmaceuticals, Inc. Common Stock reported EPS of -$0.33, beating estimates by 20.14%, and revenue of $0.00, 0% as expectations.
The stock price moved up 0.49%, changed from $12.19 before the earnings release to $12.25 the day after.
The next earning report is scheduled for ١٦ فبراير ٢٠٢٦.
Based on 17 المحللين, Oric Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.36 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان